Over the past two decades, the Cambridge area has become a nerve center for biotech in the U.S. But to stay relevant and ...
The Swiss pharma and the Medicines for Malaria Venture plan to start a Phase 3 trial of a non-artemisinin combination ...
The Danish drugmaker has invested heavily in expanding its production capacity for oral and injectable drugs. A new $744 ...
The new candidate is meant to provide broader immunity over a longer period of time and is part of the companies’ strategy to ...
Telaria is the second spinout in Replay’s “hub-and-spoke” model, and will focus on developing a gene therapy for recessive ...
Healthcare technology companies are delaying initial share sales and searching for new sources of cash. Experts don’t expect ...
The British drugmaker has begun the process of withdrawing its multiple myeloma treatment Blenrep following a request from ...
The deal is Merck’s second notable acquisition in the past year and a half, part of a strategy to diversify its pipeline ...
Our latest research uncovers new insights on how brands can truly close the wellness gap and grow within their industry ...
Regeneron will pay CytomX $30 million to try to create bispecific antibody drugs that are safer and have a wider reach than ...
Eight months after Daiichi Sankyo shuttered the San Francisco Bay Area subsidiary, Plexxikon’s former CEO is resuscitating ...
Provention Bio’s teplizumab is meant to prevent the onset of Type 1 diabetes. To be sold as Tzield, the drug will cost ...